MiMedx (MDXG) Files 8-K: Updated Presentation for Sept 3, 2025

MiMedx Group, Inc. (MDXG) disclosed that it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation.

Rhea-AI Filing Summary

MiMedx Group, Inc. (MDXG) disclosed that it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. The presentation materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated by reference. The filing reiterates standard forward-looking statement language, noting that actual results may differ due to risks such as uncertain future sales, reimbursement dynamics, scientific outcomes, international commercialization challenges, and regulatory developments. The disclosure clarifies that the furnished information is not deemed "filed" for certain Exchange Act liabilities and is not automatically incorporated into other securities filings.

Insights

Securities Analyst

TL;DR: Routine Regulation FD disclosure of an investor presentation for a September 3, 2025 conference; no new financial data provided.

This Form 8-K primarily serves to update investors and satisfy Regulation FD by furnishing presentation materials for the Cantor Global Healthcare Conference. The filing contains customary forward-looking statement disclaimers and legal language limiting incorporation and Section 18 liability. There are no financial statements, earnings figures, transaction details, or material agreements disclosed. From a market-impact perspective, this is informational and unlikely to be material unless the presentation (Exhibit 99.1) itself contains previously undisclosed material items.

Investor Relations Specialist

TL;DR: Disclosure improves investor access to management messaging but does not alter fundamentals.

Providing the updated investor presentation ahead of a conference is standard practice to maintain transparency and equal access to information. The filing's explicit non-incorporation language is typical and limits downstream legal exposure. Investors seeking material updates should review Exhibit 99.1 directly; absent that exhibit's content in this filing, the 8-K itself conveys only the event participation and availability of presentation materials.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did MiMedx (MDXG) disclose in this Form 8-K?

The company disclosed it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and furnished an updated investor presentation as Exhibit 99.1 to the Form 8-K.

Does the 8-K include financial results or transaction details for MDXG?

No. The filing does not contain earnings data, financial statements, major transactions, or material agreements—only the presentation furnishing and standard forward-looking disclaimers.

Is the furnished presentation considered "filed" with the SEC?

The company states the information, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.

What risks did MiMedx highlight in its forward-looking statements?

The filing lists risks including uncertain future sales, competition, patient access and reimbursement challenges, uncertain scientific results, international commercialization factors, and regulatory developments.

Where can investors find the updated presentation referenced in the 8-K?

The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K; investors should view Exhibit 99.1 to see the full presentation content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 08:01 AM Learn about SEC filing dates

0001376339false00013763392025-09-032025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

____________________

FORM 8-K
____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 3, 2025

MIMEDX GROUP, INC.

(Exact name of registrant as specified in charter)

Florida

001-35887

26-2792552

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

MDXG

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Important Cautionary Statement

This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) our 2025 and longer term financial goals and expectations for future financial results, including levels of net sales, Adjusted EBITDA, Adjusted EBITDA margin, corporate expenses and cash; (iii) our expectations regarding the placental tissue market; (iv) our expectations regarding Medicare spending; and (v) continued growth in different care settings, are forward-looking statements. Additional forward-looking statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “goal,” “outlook,” “potential,” “will,” “preliminary,” and similar expressions, and are based on management’s current beliefs and expectations.

Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vi) we may alter the timing and amount of planned expenditures for research and development based regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.

Item 7.01    Regulation FD Disclosure.

MiMedx Group, Inc. (the “Company”) is expected to participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. A copy of the presentation materials is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

The information in this Current Report, including Exhibits 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description of Exhibit
99.1						Investor Slide Presentation dated September 3, 2025
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						MIMEDX GROUP, INC.
September 3, 2025			By:			/s/ Doug Rice
						Doug Rice Chief Financial Officer